The Muscular Dystrophy Association (MDA) recognizes today’s decision by the U.S. District Court for the District of ...

The FDA approval of the first gene therapy for Duchenne Muscular Dystrophy (DMD) by Sarepta Therapeutics is ground-breaking and designed to target the underlying cause of the disease. The Muscular ...

NEW YORK – Monday, October 28, 2024 – The Muscular Dystrophy Association and the Players Trust, the charitable arm of the Major League Baseball Players Association, are thrilled to announce that ...

More than 5,500 people in the St. Louis area are helped by the MDA each year. ST. LOUIS — 5 On Your Side’s annual telethon benefitting the Muscular Dystrophy Association is back Labor Day weekend.

Grant Awarded to Melissa Spencer, PhD, Co-Director of the Center for Duchenne Muscular Dystrophy at UCLA. New York – Tuesday, December 17, 2024 — The Muscular Dystrophy Association (MDA) and Coalition ...

MDA Summer Camp wouldn’t be possible without people like you. Each summer, hundreds of volunteers serve as counselors and medical team members during weeklong, overnight Summer Camp programs to help ...

The gene that’s defective in oculopharyngeal muscular dystrophy (OPMD) was discovered in 1998. It carries instructions for a polyadenylate binding protein (PABPN1) that’s normally present in the cell ...

Join MDA for an informative webinar focused on navigating changes to state and federal benefits. Whether you're a patient, caregiver, or advocate, this webinar will offer valuable insights, resources, ...

A place where individuals and families are at the heart of everything we do.

New York, March 10, 2025 – The Muscular Dystrophy Association (MDA) welcomes the U.S. Food and Drug Administration (FDA) approval of the expanded indication of Alexion/AstraZeneca’s eculizumab ...

The word myopathy means “disease of muscle.” More specifically, myopathies are diseases that cause problems with the tone and contraction of skeletal muscles (muscles that control voluntary movements.